Lisuride


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : PO Parkinson's disease Initial: 0.1 mg at bedtime, additional doses of 0.1 mg at wkly intervals may be given, 1st in the morning then at midday. Further increases of 0.1 mg wkly may be made until an optimum response is obtained. Max: 2 mg/day in 3 or 4 divided doses. Hyperprolactinaemia-associated disorders; Acromegaly Day 1: 0.1 mg in the evening. Day 2: 0.1 mg at midday and in the evening. Day 3: 0.1 mg in the morning, at midday and in the evening. Treatment is continued and adjusted according to prolactin levels (hyperprolactinaemia) or growth hormone levels (acromegaly). Suppression of lactation 0.2 mg bid to tid for 14 days starting w/in the 1st 24 hr of delivery or abortion.
Dosage Details
Oral
Parkinson's disease
Adult: Initially, 0.1 mg at bedtime, additional doses of 0.1 mg at wkly intervals may be given, 1st in the morning then at midday. Further increases of 0.1 mg wkly may be made until an optimum response is obtained, using the same sequence of increases, starting w/ the bedtime dose. Max: 2 mg daily in 3 or 4 divided doses.

Oral
Suppression of lactation
Adult: 0.2 mg bid to tid for 14 days starting w/in the 1st 24 hr of delivery or abortion.

Oral
Acromegaly, Hyperprolactinaemia-associated disorders
Adult: 0.1 mg in the evening of the 1st day, followed by 0.1 mg at midday and in the evening of the 2nd day, then 0.1 mg in the morning, at midday and in the evening of the 3rd day. Treatment is continued and adjusted according to prolactin levels (hyperprolactinaemia) or growth hormone levels (acromegaly).
Administration
Should be taken with food. Always take w/ a meal or snack.
Contraindications
Serious peripheral arterial disorders and coronary insufficiency. Concomitant use w/ phenylpropanolamine.
Special Precautions
Patient w/ past or present psychosis. Avoid abrupt withdrawal. Pregnancy and lactation.
Adverse Reactions
Nausea, vomiting, dry mouth, obstipation, peripheral oedema, sweating, hallucination, anxiety, confusion, nightmares, insomnia, decreased appetite, dyskinesia, somnolence, vertigo, headache, dystonia, myoclonus, orthostatic hypotension, cold extremities, erythromelalgia, palpitation, dyspnoea.
Patient Counseling Information
This drug may cause somnolence, if affected, do not drive or operate machinery.
MonitoringParameters
Monitor regularly for development of impulse control disorders.
Overdosage
Symptoms: Severe dopamine-agonistic reactions e.g. nausea, vomiting and vertigo. Management: Metoclopramide oral drops (or domperidone in parkinsonism) may be given as antidote for mild cases. Severe cases may be treated w/ IM sulpiride 100 mg.
Drug Interactions
Enhanced sedative effect w/ drugs that have CNS depressant effects (e.g. benzodiazepines, antipsychotics). Mutual antagonistic effect w/ antipsychotic neuroleptics (except clozapine). Risk of vasoconstriction and/or hypertensive crisis w/ sympathomimetics (alpha and indirect) and vasoconstrictive ergot alkaloids. Increased risk of neuropsychic disorders w/ anticholinergic antiparkinsonians. Effects may be attenuated by neuroleptics and other dopamine antagonists.
Potentially Fatal: Risk of vasoconstriction and/or hypertensive crises w/ phenylpropanolamine.
Food Interaction
Enhanced sedative effect w/ alcohol.
Action
Description: Lisuride directly stimulates postsynaptic dopamine receptors, thereby improving or eliminating the reduced locomotion, rigor and tremor. It also suppresses the normal production and flow of milk and improves pathological states of the mammary gland.
Pharmacokinetics:
Absorption: Rapidly and completely absorbed. Time to peak plasma concentration: 1.1-1.3 hr.
Distribution: Widely distributed into the body. Volume of distribution: 2.3 L/kg. Plasma protein binding: 66%.
Metabolism: Undergoes hepatic metabolism, mainly via oxidation pathways including N'-desalkylation of ethyl groups, hydroxylation of the benzene ring, mono-oxygenation and oxidation of double bonds.
Excretion: Via urine, as metabolites. Plasma elimination half-life: 10 hr.
Chemical Structure

Click on icon to see table/diagram/image
Storage
Store below 30°C. Protect from light.
ATC Classification
N02CA07 - lisuride ; Belongs to the class of ergot alkaloids preparations. Used to relieve migraine.
G02CB02 - lisuride ; Belongs to the class of prolactine inhibitors. Used to suppress lactation.
Disclaimer: This information is independently developed by MIMS based on Lisuride from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in